Loading
Each congress, distilled to the findings that changed something in this map, with a source for every item and links to the technologies, products, and trials it touches.
Triple-negative breast cancer moved to an ADC-first world, the largest cancer screening trial ever run reported mixed results, and immunotherapy kept extending its reach in the curative setting.
Oral SERDs and PROTACs consolidated their place in ESR1-mutant disease, T-DXd de-escalation strategies matured in HER2+ early breast cancer, and the limits of giving one ADC straight after another became clearer.
The next ADC generation showed its shape: bispecific and dual-payload constructs, new targets (MERTK, CDCP1, LRRC15, STn, integrin αvβ6, ALPP), and AI-nominated antigens, almost all carrying topoisomerase-I payloads.
Alpha-emitting PSMA therapy produced its cleanest first-in-human data yet, and PSMA PET continued to reshape staging and treatment selection.
7,222 abstracts published in Journal of Clinical Oncology between 2026-05-10 and 2026-06-20 (via Crossref), of which 400 name a product or trial in OnCo. Late-breaking abstracts first, then the most connected. A digest for this congress already exists; use the links to propose additions.
Digests are written by hand from sources named on each item. The candidate list above is harvested weekly from the congress supplements (DOI records via Crossref) and matched to products and trials in OnCo; it is a reading list for the editor, not a digest. Feed status: when each feed last ran.